


Original Article

Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic

Kayla R. Maki PharmD¹, Samantha N. Steiger PharmD¹, Yiqi Su MS², Aida Boumiza BA², Carrie A. Tan PharmD¹, Marina Kerpelev BS³, Susan K. Seo MD^{2,4,a}  and Nina Cohen PharmD^{1,a}

¹Department of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, New York, ²Infectious Diseases Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, ³Information Systems, Memorial Sloan Kettering Cancer Center, New York, New York and ⁴Department of Medicine, Weill Cornell Medical College, New York, New York

Abstract

Objective: To characterize bacterial infections and antibiotic utilization in hospitalized cancer patients with coronavirus disease 2019 (COVID-19).

Design: Retrospective cohort study.

Setting: Tertiary cancer center in New York City.

Patients: Hospitalized cancer patients ≥ 18 years with COVID-19 between March 1, 2020, and May 31, 2020.

Methods: Patients were classified with mild COVID-19 (ie, with room air), moderate COVID-19 (ie, using nasal cannula oxygen), or severe COVID-19 (ie, using high-flow oxygen or mechanical ventilation). The primary outcome was bacterial infection rate within 30 days of COVID-19 onset. Secondary outcomes included the proportion of patients receiving antibiotics and antibiotic length of therapy (LOT).

Results: Of 358 study patients, 133 had mild COVID-19, 97 had moderate COVID-19, and 128 had severe COVID-19. Of 358 patients, 234 (65%) had a solid tumor. Also, 200 patients (56%) had 245 bacterial infections, of which 67 (27%) were microbiologically confirmed. The proportion of patients with bacterial infection increased with COVID-19 severity: mild ($n = 47$, 35%) versus moderate ($n = 49$, 51%) versus severe ($n = 104$, 81%) ($P < .0001$). Also, 274 (77%) received antibiotics for a median of 4 days. The median antibiotic LOTs were 7 days with 1 infection and 20 days with multiple infections ($P < .0001$). Antibiotic durations were 1 day for patients with mild COVID-19, 4 days for patients with moderate COVID-19, and 8 days for patients with severe COVID-19 ($P < .0001$).

Conclusions: Hospitalized cancer patients with COVID-19 had a high rate of bacterial infection. As COVID-19 severity increased, the proportion of patients diagnosed with bacterial infection and given antibiotics increased. In mild COVID-19 cases, antibiotic LOT was short, suggesting that empiric antibiotics can be safely avoided or discontinued in this group.

(Received 24 December 2021; accepted 21 April 2022; electronically published 26 May 2022)

Coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a global pandemic that is ongoing.¹ Early reports suggested that patients with cancer on active therapy were at higher risk for severe COVID-19–related events.^{2,3} In an analysis of 423 cases of symptomatic COVID-19 diagnosed at a cancer center in the United States between March 10 and April 7, 2020, 163 (40%)

required hospitalization, 87 (20%) developed severe respiratory illness, and 51 (12%) died within 30 days.⁴ Patients with hematologic or lung malignancies, peri-COVID-19 lymphopenia, or baseline neutropenia had worse outcomes.⁵ Even in the absence of COVID-19, these and other factors (eg, cytotoxic chemotherapy, other immunosuppressive therapy, anatomic derangements, central venous catheters) portend infectious risk for cancer patients.

Since the onset of the COVID-19 pandemic, several studies have reported frequent prescription of broad-spectrum empiric antibiotics despite low rates of microbiologically confirmed bacterial infections diagnosed around the time of SARS-CoV-2 infection.^{6–8} As patients extend their hospitalization beyond 48 hours, nosocomial bacterial infections appear to be more frequent, particularly among patients admitted to the intensive care unit (ICU).^{8,9} However, data on infectious complications

Author for correspondence: Nina Cohen, PharmD, E-mail: cohenn@mskcc.org

PREVIOUS PRESENTATION. These data were presented in a poster at the 2020 American Society of Health System Pharmacists Midyear Meeting on December 6–10, 2020, held virtually. Poster number RP-554, on December 10, 2020.

^aAuthors of equal contribution.

Cite this article: Maki KR, et al. (2023). Bacterial infections and antibiotic utilization varies by coronavirus disease 19 (COVID-19) severity in hospitalized cancer patients: Analysis from the first phase of the pandemic. *Infection Control & Hospital Epidemiology*, 44: 413–419, <https://doi.org/10.1017/ice.2022.129>



specific to cancer patients infected with SARS-CoV-2 are scarce. The purpose of this study was to characterize bacterial infections and antibiotic utilization in hospitalized cancer patients with COVID-19 at a tertiary-care cancer center between March 1, 2020, and May 31, 2020.

Methods

Study population and design

This study was reviewed and approved by the institutional review board at Memorial Sloan Kettering Cancer Center (MSKCC), a 498-bed tertiary cancer center in New York, New York. Hospitalized adults ≥ 18 years of age diagnosed with COVID-19 between March 1, 2020, and May 31, 2020 were included in the study. SARS-CoV-2 was detected by nasopharyngeal polymerase chain reaction (PCR). The institutional electronic health record was used to obtain clinical information, as well as laboratory, microbiology, and radiology results for each hospitalization. Abstracted data included demographics, underlying cancer diagnosis, medical comorbidities, anti-infectives and dates of administration, supplemental oxygen support, intensive care unit (ICU) stay, noninvasive and invasive ventilatory support, and pressor support. The primary outcome was the rate of bacterial infection within 30 days of the date of COVID-19 diagnosis. Secondary outcomes included the proportion of patients receiving antibiotics and antibiotic length of therapy (LOT) initiated within 30 days of COVID-19 diagnosis. Prophylactic antibiotics (eg, trimethoprim-sulfamethoxazole for *Pneumocystis jirovecii* prevention) and anti-infectives lacking antibacterial activity were excluded. Outpatient antibiotic prescriptions were also excluded since there would not be a way to verify patient's compliance. Antibiotics were grouped by therapeutic class.¹⁰

Role of the institutional antimicrobial stewardship program (ASP) during the pandemic

At the start of the COVID-19 pandemic, the hospital's ASP team members along with the infectious disease (ID) service drafted guidelines for therapeutic management of patients with COVID-19. Institutional guidelines, which were posted on the hospital's intranet, considered risk stratification not only by need for hospitalization and oxygenation status but also the degree of immunosuppression. As data emerged on efficacy and safety of therapeutics (eg, remdesivir or dexamethasone) for COVID-19 management, institutional guidelines were revised in real time. In addition, the ASP maintained stewardship interventions such as prior approval for restricted antibiotics (eg, piperacillin-tazobactam, cefepime, ceftriaxone, carbapenems, fluoroquinolones, and azithromycin) and postprescription review and feedback during the pandemic.

Definitions

Because oxygenation status can vary during the COVID-19 course of illness, we categorized COVID-19 severity based on the maximum oxygen requirement during the hospitalization. Patients were classified as having mild COVID-19 if no supplemental oxygen was used, moderate COVID-19 if a nasal cannula was used, or severe COVID-19 if high-flow oxygen or mechanical ventilation was used.

An infectious episode was defined as the presence of clinical symptoms along with supporting laboratory, microbiologic (if

available), and radiographic results documented in admission and daily progress notes by the primary teams. Definitions for bacterial infections were based on standard definitions from national society guidelines (Supplementary Material online).^{11–19} Patients who were classified as having fever and neutropenia had preceding cytotoxic chemotherapy. Suspected bacterial infections without microbiologic confirmation were also included. Despite testing positive for SARS-CoV-2, patients with respiratory symptoms and radiographic infiltrates warranting empiric antibacterial treatment within 48 hours of admission were considered to have community-acquired pneumonia (CAP). If a patient had clinical worsening combined with a new infiltrate on chest imaging, the patient was considered to have hospital-acquired pneumonia (HAP) if the symptoms were not incubating at the time of admission and worsening occurred ≥ 48 hours after admission or the patient was considered to have ventilator-associated pneumonia (VAP) if worsening occurred >48 hours after endotracheal intubation.

Antibiotic LOT was defined as the number of days that a patient received systemic antimicrobial agents, irrespective of the number of different drugs.²⁰ Antibiotic days of therapy (DOT) was defined as the number of days that a patient received an antimicrobial agent; the DOT for a given patient on multiple antibiotics was the sum of DOT for each antibiotic that the patient received.²⁰

Statistical analysis

Descriptive statistics were used to tabulate demographic characteristics and outcomes. Numeric data were expressed as medians (interquartile range, IQR) and were compared using the Mann-Whitney rank-sum test or the Kruskal-Wallis test across groups as appropriate. Categorical data were compared using the χ^2 test or the Fisher exact test across groups and are reported as number (percentage). The Cochran-Armitage and Jonckheere-Terpstra tests were used to assess the increasing trends of proportion of patients given antibiotics and the median antibiotic LOT by ordinal COVID-19 severity, respectively.

Results

In total, 358 hospitalized patients were diagnosed with COVID-19 between March 1, 2020, and May 31, 2020. Patient characteristics and outcomes are listed in Table 1. Among the 358 patients, 234 (65%) had solid-tumor malignancies. Also, 166 patients (46%) were evaluated by the infectious disease (ID) service. Patients with mild COVID-19 were significantly younger than those with moderate or severe disease: mild COVID-19 (median age, 62 years) versus moderate COVID-19 (median age, 67 years) versus severe COVID-19 (median age, 67 years) ($P = .004$). Statistically significant differences in 30-day mortality, median hospital length of stay (LOS), the proportion of patients admitted to the ICU, and the proportion of intubated patients were observed along the spectrum of mild, moderate, and severe COVID-19 (Table 1). Furthermore, 200 patients (56%) were diagnosed with at least 1 bacterial infection, and 42 (21%) of these 200 were neutropenic when diagnosed with the bacterial infection. The proportion of patients diagnosed with a bacterial infection increased with COVID-19 severity: 47 patients (35%) had mild COVID-19, 49 (51%) had moderate COVID-19, and 104 (81%) had severe COVID-19 ($P < .0001$). Similar results were observed when restricting to patients with microbiologically documented bacterial infections: 16 (12%) had

Table 1. Comparison of Patient Characteristics and Outcomes by COVID-19 Severity

| Characteristic | Total (N=358) | Mild (N=133) | Moderate (N=97) | Severe (N=128) | P Value |
|---|---------------|--------------|-----------------|----------------|---------|
| Age, median y (IQR) | 65 (55, 74) | 62 (49, 72) | 67 (56, 73) | 67 (60, 75) | .004 |
| Sex, male, no. (%) | 180 (50) | 63 (47) | 50 (52) | 67 (52) | .694 |
| Malignancy, no. (%) | | | | | .189 |
| Hematologic | 119 (33) | 43 (32) | 27 (28) | 49 (38) | |
| Solid | 234 (65) | 88 (66) | 67 (69) | 79 (62) | |
| Unknown | 5 (1) | 2 (2) | 3 (3) | 0 (0) | |
| 30-d mortality, no. (%) | 57 (16) | 2 (2) | 7 (7) | 48 (38) | <.0001 |
| Hospital LOS, median d (IQR) | 9 (5–17) | 6 (3–9) | 9 (6–15) | 16 (10–32) | <.0001 |
| ICU stay, no. (%) | 79 (22) | 2 (2) | 7 (7) | 70 (55) | <.0001 |
| Ventilator use, no. (%) | 54 (15) | 0 (0) | 0 (0) | 54 (42) | <.0001 |
| Patients with ≥ 1 bacterial infection, no. (%) | 200 (56) | 47 (35) | 49 (51) | 104 (81) | <.0001 |
| Patients with microbiologically confirmed bacterial infections, no. (%) | 59 (16) | 16 (12) | 11 (11) | 32 (25) | .0052 |
| Proportion given antibiotics, no. (%) | 274 (77) | 78 (59) | 73 (75) | 123 (96) | <.0001 |
| Antibiotic LOT, median d (IQR) | 4 (1–8) | 1 (0–4) | 4 (1–6) | 8 (5–16) | <.0001 |

Note. IQR, interquartile range; ICU, intensive care unit; LOS, length of stay; LOT, length of therapy.

mild COVID-19, 11 (11%) had moderate COVID-19 and 32 (25%) had severe COVID-19 ($P = .0052$).

In total, 245 bacterial infections were diagnosed in 200 patients; 42 patients had >1 bacterial infection. Types of bacterial infections as well as the rates of microbiologically confirmed infections are shown in Table 2. Of 245 infections, 163 (67%) were diagnosed within 48 hours of admission. The predominant infection involved the lower respiratory tract, which occurred in 140 patients. Among these patients, 19 (14%) had 2 episodes. Neutropenia was present in 12 (8%) of 159 episodes of pneumonia. Furthermore, 105 patients (66%) were classified as having community-acquired pneumonia (CAP), and 88 (84%) of these patients required oxygen supplementation. Of 105 (82%) patients with a CAP diagnosis, 86 also had a respiratory PCR (BioFire FilmArray RP2, Salt Lake City, UT), urine *Legionella* antigen test (BinaxNow, Abbott, Chicago, IL), a streptococcal urine antigen test (BinaxNow, Abbott, Chicago, IL), and/or sputum culture sent. However, none was positive for a bacterial organism. Of 105 patients, 52 (50%) were evaluated by the ID service, and empiric antibiotics for CAP were deemed appropriate. Also, 2 patients with empyema had a bacterial organism identified from pleural fluid.

Of these 159 patients, 19 (12%) had bacteria recovered from a respiratory specimen: *Achromobacter xylosoxidans/denitrificans* ($n = 1$), *Burkholderia cepacia* ($n = 1$), coagulase-negative *Staphylococcus* spp ($n = 1$), *Escherichia coli* ($n = 2$), *Klebsiella pneumoniae* ($n = 1$), methicillin-resistant *Staphylococcus aureus* ($n = 1$), *Pseudomonas aeruginosa* ($n = 5$, 2 isolates were multi-drug-resistant), *Pseudomonas* spp ($n = 2$), *Serratia marcescens* ($n = 1$), *Streptococcus anginosus* ($n = 1$), *Streptococcus pneumoniae* ($n = 1$), and polymicrobial ($n = 2$), 1 patient had *P. aeruginosa* and *Stenotrophomonas maltophilia*, 1 patient had carbapenem-resistant *K. pneumoniae* and *P. aeruginosa*. Other types of bacterial infections occurred far less frequently ($<10\%$) (Table 2).

Table 3 lists the median antibiotic LOT by infection type for patients with a single infection. In patients without a diagnosed bacterial infection, the median antibiotic LOT was 0 days (IQR,

Table 2. Classification of Bacterial Infection

| Infection Type | Total Infections, No. (%) ^a | Microbiologically Confirmed Infections, No. (%) | Nosocomial-Onset Infections (>48 h Admission), No. (%) |
|-----------------------|--|---|---|
| Bloodstream | 9 (4) | 9 (100) | 5 (56) |
| Fever and neutropenia | 23 (9) | 0 (0) | 4 (17) |
| Gastrointestinal | 22 (9) | 16 (73) | 11 (50) |
| Respiratory | 159 (65) | 19 (12) | 52 (33) |
| Skin and soft tissue | 10 (4) | 3 (30) | 3 (30) |
| Urinary | 22 (9) | 20 (91) | 7 (32) |
| Total | 245 (100) | 67 (27) | 82 (33) |

^a42 patients had >1 infection.

0–2), whereas the median antibiotic LOTs were 7 days (IQR 4, 9) for those with 1 infection and 20 days (IQR, 14–29) for patients with multiple infections ($P < .0001$). Differences in the median antibiotic LOT were also observed as COVID-19 severity increased (Table 1). The median antibiotic LOT was short in patients with mild COVID-19 (1 day; IQR, 0–4) in comparison to those with moderate COVID-19 (4 days; IQR, 1–6) and severe COVID-19 (8 days; IQR, 5–16) ($P < .0001$). Figure 1 shows the cumulative antibiotic days of therapy by therapeutic class. The 5 most frequently administered antibiotics were piperacillin-tazobactam, cefepime, ceftriaxone, azithromycin, and meropenem.

Discussion

We describe bacterial infections and antibiotic utilization in hospitalized cancer patients diagnosed with COVID-19 between

Table 3. Comparison of Antibiotic Length of Therap (LOT) by Infection Type for Patients with a Single Bacterial Infection

| Infection Type | Single Infection, No. (%) | Antibiotic LOT, Median (IQR) |
|-----------------------|---------------------------|------------------------------|
| Bloodstream | 5 (3) | 3 (2–7) |
| Fever and neutropenia | 14 (9) | 6 (3–9) |
| Gastrointestinal | 10 (6) | 4 (4–6) |
| Respiratory | 106 (67) | 7 (5–9) |
| Skin and soft tissue | 9 (6) | 7 (4–8) |
| Urinary | 14 (9) | 6 (3–10) |
| Total | 158 (100) | 7 (4–9) |

Note. IQR interquartile range.

March 1, 2020, and May 31, 2020, in New York City, an early epicenter of the COVID-19 pandemic in the United States. More than half of the study patients were diagnosed with a bacterial infection during the hospitalization, and pneumonia accounted for the bulk of infections. Most patients received antibiotics, but the median durations were within recommended lengths for the types of infection observed. Rates of bacterial infection and antibiotic prescribing, as well as antibiotic durations increased with increasing COVID-19 severity.

Rates of microbiologically confirmed bacterial respiratory and bloodstream infections in hospitalized patients during the initial COVID-19 surge range from 2.3% to 8.2%, but data specific to cancer patients are limited.^{6,8,21–24} Our investigation of SARS-CoV-2-infected cancer patients revealed an overall higher rate of microbiologically confirmed bacterial infections (27%), although other infection types were included. Pneumonia was commonly diagnosed, but only 19 (12%) of 159 cases had positive respiratory cultures. In the only other study examining hospitalized patients with cancer and COVID-19, the rate of microbiologically documented bacterial infections was 17%.²⁵ Gudiol et al²⁵ also reported that lower respiratory tract infections (67 of 167, 40%) were common in their patient cohort, but there was a higher diagnostic yield, with only 17 (25%) of 67 cases having no organisms identified.²⁵ Notably, bacterial infection rates, particularly for pneumonias, may be underestimated if only microbiologically confirmed infections are counted.

Among the 140 lower respiratory tract infections without a bacterial microbiologic diagnosis in our study, 103 were CAP and 37 were HAP or VAP. Among the 37 HAP and VAP cases, 2 were diagnosed with a probable invasive fungal infection (1 pulmonary aspergillosis, 1 pulmonary coccidiomycosis). Of the 35 remaining HAP and VAP cases, these patients had clinical worsening in the setting of a new radiographic infiltrate, suggesting nosocomial superinfection. We acknowledge that the 103 cases designated as CAP could have solely been from SARS-CoV-2 infection. Clinical symptoms such as fever, cough, and shortness of breath combined with abnormal chest imaging (eg, lobar consolidation, ground glass opacities, reticular infiltrates) have been well described in patients with lower respiratory tract involvement with COVID-19.²⁶ This clinical picture, however, is nonspecific because bacterial pneumonia can also present similarly.^{15,16}

Several studies have noted reduced respiratory sampling (7.7%–17.7%) during the pandemic because patients may not have been able to produce phlegm and/or fewer diagnostic procedures

(eg, bronchoscopy) may have been performed due to concerns about healthcare worker safety.^{8,24} The poor sensitivity of cultures and incomplete use of diagnostic tests are other well-recognized limitations.^{15,27} Even under circumstances in which all available tests are submitted, diagnostic yield remains low. In a large population-based surveillance study for CAP, blood, urine, and respiratory specimens were systematically collected for culture, serologic testing, antigen detection, and molecular diagnostic testing, but a bacterial pathogen was detected in only 247 (11%) of 2,259 individuals.²⁷ According to the 2019 American Thoracic Society and Infectious Diseases Society of America guidelines in the pre-COVID-19 era, routine testing is recommended only for patients with severe CAP or if there are concerns for multi-drug-resistant pathogens.²⁸ Thus, CAP diagnosis does not rely on microbiologic confirmation. One area that warrants further investigation is whether SARS-CoV-2 can predispose a patient to bacterial pneumonia, similar to what has been demonstrated with influenza virus.²⁹ Because bacterial coinfection in critically ill patients has ranged from 23% to 30% in past influenza epidemics, antibacterial treatment is recommended in adults with clinical and radiographic evidence of CAP who test positive for influenza.^{28,30} A recent case series showed that coinfection with bacterial pathogens (including *Mycoplasma* and *Chlamydia*) did occur in patients who died from COVID-19 pneumonia.³¹ The true picture of bacterial coinfection is thus not clear because it has been challenging to definitively include or exclude other concomitant bacterial etiologies in SARS-CoV-2-infected patients with lower respiratory tract findings.

Compared with the general patient population, cancer patients have a higher infectious morbidity and mortality due to the underlying malignancy and/or its treatment. This disparity is borne out in our study by an additional 77 infections (31%) not involving the respiratory tract or bloodstream and included fever and neutropenia, gastrointestinal infections, skin and soft-tissue infections, and urinary tract infections. In contrast, only 1,002 (2%) of 48,092 hospitalized patients infected with SARS-CoV-2 from the United Kingdom were diagnosed with other bacterial infections in addition to pneumonia or bacteremia.⁸

It is not surprising that 274 (77%) of 358 patients in this study were exposed to antibiotics during their COVID-19 admission. Many other studies have noted high rates (ie, >70%) of antibiotic administration in hospitalized SARS-CoV-2-infected patients.^{6,7,32} However, the proportion of patients diagnosed with a bacterial infection and given antibiotics differed by severity of illness. Although this finding seems intuitive, no prior study has systematically assessed both parameters (bacterial infection and antibiotic utilization) along with COVID-19 severity. In patients with mild COVID-19, 47 (35%) of 133 were diagnosed with a bacterial infection and 78 (59%) received empiric antibiotics for a median of 1 day. Thus, the data suggest that hospitalized cancer patients with mild COVID-19 can avoid or have early discontinuation of empiric antibiotics with active antimicrobial stewardship oversight. Other hospital ASPs have shown that they could discontinue or narrow antibiotics for CAP in patients with COVID-19 within 72 hours of admission.^{33,34} This finding contrasts with a report by Cong et al,³² who reviewed 118 publications and stratified patients with COVID-19 into mild-to-moderate or severe-to-critical illness categories. Antibiotic prescribing during the first 6 months of the COVID-19 pandemic was high (>75%) in both groups. This highlights the potential role that ASPs can play to better optimize anti-infectives during pandemics.




Fig. 1. Cumulative antibiotic days of therapy. Extended-spectrum penicillins: piperacillin-tazobactam; fourth-generation cephalosporins: ceftazidime, ceftazidime-avibactam, ceftolozane-tazobactam, ceftriaxone; third-generation cephalosporins: cefixime, ceftazidime, ceftazidime-avibactam, ceftolozane-tazobactam, ceftriaxone; macrolides: azithromycin; carbapenems: meropenem; glycopeptides (iv): vancomycin; glycopeptides (oral): vancomycin; monobactams: aztreonam; quinolones: ciprofloxacin, levofloxacin; aminopenicillins: amoxicillin-clavulanate, ampicillin, ampicillin-sulbactam; first generation cephalosporins: cefadroxil, cefazolin, cephalexin; amebicides: metronidazole; oxazolidinones: linezolid; fifth-generation cephalosporins: ceftaroline; lincomycins: clindamycin; second generation cephalosporins: cefuroxime; sulfonamides: trimethoprim-sulfamethoxazole; urinary anti-infectives: nitrofurantoin; aminoglycosides: amikacin; cyclic lipopeptides: daptomycin. Note. gen, generation; IV, intravenous.

In more severely ill patients, the risk and rate of bacterial infection are higher. Because COVID-19 in patients with cancer is marked by substantial rates of hospitalization, severe outcomes, and additional difficulty in discriminating bacterial infection from severe COVID-19 inflammation, the administration of empiric antibiotic therapy under these circumstances is understandable.^{4,35} In our study, nearly all patients who required high-flow oxygen or mechanical ventilation (severe COVID-19) were prescribed antibiotics, and 104 (81%) of 128 patients were diagnosed with a bacterial infection. Even so, the median antibiotic LOT for study patients with severe COVID-19 was 8 days. Martin et al³⁶ similarly noted that ICU stay and the necessity for mechanical ventilation were predictors for antibiotic prescribing in hospitalized patients with COVID-19.

In examining antibiotic duration by infection type, the median antibiotic LOT for bacterial infections was not overly long and was consistent with standard duration of therapy. Both ASP members and ID consultation teams strived to maintain standard duration of therapy for suspected or documented bacterial infections and actively discontinued empiric antibiotic therapy in cases where bacterial etiology was unlikely. For example, the median antibiotic LOT for respiratory infections was 7 days, which was in line with national guidelines for CAP, HAP, and VAP.^{15,28} Of the 5 patients who had a bloodstream infection, the median antibiotic LOT was short because 3 patients died. Similar to other studies, broad-spectrum antibiotics (eg, piperacillin/tazobactam, ceftazidime, meropenem) as well as agents used for respiratory infections were the most commonly prescribed agents between March 2020 and May 2020.^{37–39}

This study had several limitations. In this is single-center retrospective study, we also included clinically diagnosed bacterial infections without microbiologic confirmation. This method may have led to an overestimation of infection rates, specifically lower-respiratory-tract infections of which CAP was predominant. Although fever, respiratory symptoms, and lung infiltrates could all be due to COVID-19, there is conversely insufficient high-quality evidence to safely withhold antibacterial therapy in hospitalized cancer patients, most of whom required supplemental oxygen in our study. Patients with multiple bacterial infections can have overlapping antibiotic therapy, so we looked at patients with a single infection so that we could clearly identify antibiotic duration by infection type. Although the exclusion of patients with multiple bacterial infections could lead to the underestimation of antibiotic LOT, the number of patients with multiple infections was small. Antibiotic LOT could also have been underestimated because we did not include outpatient prescriptions given upon hospital discharge. The results of this study may not be generalizable to non-cancer settings or institutions that lack a robust ASP. Also, these findings may not be generalizable to later surges from SARS-CoV-2 viral variants of concern [eg, δ (delta) and (omicron) variants]. The development of COVID-19 therapeutics (eg, antivirals, monoclonal antibodies) and a higher proportion of vaccinated individuals should reduce the proportion of cancer patients who require hospitalization and/or who develop severe COVID-19.

In conclusion, hospitalized cancer patients with COVID-19 had a high rate of bacterial infections. Although antibiotic prescribing was common, the proportion of patients diagnosed with a bacterial infection and given antibiotics increased as patients developed

more severe COVID-19. Median durations of antibiotic therapy were within recommended lengths for the types of infections seen. In mild COVID-19 cases, antibiotic therapy was short, suggesting that empiric antibiotics can be safely avoided or stopped in this group.

Supplementary material. To view supplementary material for this article, please visit <https://doi.org/10.1017/ice.2022.129>

Acknowledgments.

Financial support. This research was funded in by the NIH/NCI Cancer Center (grant no. P30 CA008748).

Conflicts of interest. All authors report no conflicts of interest relevant to this article.

References

- Wang D, Hu B, Hu C, *et al*. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. *JAMA* 2020;323:1061–1069.
- Yu J, Ouyang W, Chua MLK, Xie C. SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China. *JAMA Oncol* 2020;6:1108–1110.
- Liang W, Guan W, Chen R, *et al*. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. *Lancet Oncol* 2020;21:335–337.
- Robilotti EV, Babady NE, Mead PA, *et al*. Determinants of COVID-19 disease severity in patients with cancer. *Nat Med* 2020;26:1218–1223.
- Jee J, Foote MB, Lumish M, *et al*. Chemotherapy and COVID-19 outcomes in patients with cancer. *J Clin Oncol* 2020;38:3538–3546.
- Nori P, Cowman K, Chen V, *et al*. Bacterial and fungal coinfections in COVID-19 patients hospitalized during the New York City pandemic surge. *Infect Control Hosp Epidemiol* 2021;42:84–88.
- Rawson TM, Moore LSP, Zhu N, *et al*. Bacterial and fungal coinfection in individuals with coronavirus: a rapid review to support COVID-19 antimicrobial prescribing. *Clin Infect Dis* 2020;71:2459–2468.
- Russell CD, Fairfield CJ, Drake TM, *et al*. Coinfections, secondary infections, and antimicrobial use in patients hospitalised with COVID-19 during the first pandemic wave from the ISARIC WHO CCP-UK study: a multicentre, prospective cohort study. *Lancet Microbe* 2021;2:e354–e365.
- Garcia-Vidal C, Sanjuan G, Moreno-Garcia E, *et al*. Incidence of coinfections and superinfections in hospitalized patients with COVID-19: a retrospective cohort study. *Clin Microbiol Infect* 2021;27:83–88.
- American Hospital Formulary Service. AHFS Pharmacologic-Therapeutic Classification System. Oregon government website. [https://www.oregon.gov/obnm/Documents/Formulary%20Information/AHFS ClassificationwithDrugs2019.pdf](https://www.oregon.gov/obnm/Documents/Formulary%20Information/AHFS%20ClassificationwithDrugs2019.pdf). Accessed November 11, 2021.
- Bloodstream infection event (central-line-associated bloodstream infection and non-central-line-associated bloodstream infection). Centers for Disease Control and Prevention website. https://www.cdc.gov/nhsn/pdfs/pscmanual/4psc_clabscurrent.pdf. Accessed November 2, 2021.
- Cohen SH, Gerding DN, Johnson S, *et al*. Clinical practice guidelines for *Clostridium difficile* infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol* 2010;31:431–455.
- Freifeld AG, Bow EJ, Sepkowitz KA, *et al*. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2011;52:e56–e93.
- Gupta K, Hooton TM, Naber KG, *et al*. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. *Clin Infect Dis* 2011;52:e103–e120.
- Kalil AC, Metersky ML, Klompas M, *et al*. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis* 2016;63:e61–e111.
- Mandell LA, Wunderink RG, Anzueto A, *et al*. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. *Clin Infect Dis* 2007;44 suppl 2:S27–S72.
- Shane AL, Mody RK, Crump JA, *et al*. 2017 Infectious Diseases Society of America clinical practice guidelines for the diagnosis and management of infectious diarrhea. *Clin Infect Dis* 2017;65:e45–e80.
- Solomkin JS, Mazuski JE, Bradley JS, *et al*. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. *Clin Infect Dis* 2010;50:133–164.
- Stevens DL, Bisno AL, Chambers HF, *et al*. Practice guidelines for the diagnosis and management of skin and soft-tissue infections: 2014 update by the Infectious Diseases Society of America. *Clin Infect Dis* 2014;59:e10–e52.
- Antimicrobial stewardship programs (ASPs) metrics examples. Public Health Ontario website. <https://www.publichealthontario.ca/-/media/documents/A/2017/asp-metrics-examples.pdf>. Accessed November 2, 2021.
- Arentz M, Yim E, Klaff L, *et al*. Characteristics and outcomes of 21 critically ill patients with COVID-19 in Washington State. *JAMA* 2020;323:1612–1614.
- Cheng LS, Chau SK, Tso EY, *et al*. Bacterial coinfections and antibiotic prescribing practice in adults with COVID-19: experience from a single hospital cluster. *Ther Adv Infect Dis* 2020;7:2049936120978095.
- Goyal P, Choi JJ, Pinheiro LC, *et al*. Clinical characteristics of COVID-19 in New York City. *N Engl J Med* 2020;382:2372–2374.
- Vaughn VM, Gandhi TN, Petty LA, *et al*. Empiric antibacterial therapy and community-onset bacterial coinfection in patients hospitalized with coronavirus disease 2019 (COVID-19): a multihospital cohort study. *Clin Infect Dis* 2021;72:e533–e541.
- Gudiol C, Dura-Miralles X, Aguilar-Company J, *et al*. Coinfections and superinfections complicating COVID-19 in cancer patients: a multicentre, international study. *J Infect* 2021;83:306–313.
- Metlay JP, Waterer GW. Treatment of community-acquired pneumonia during the coronavirus disease 2019 (COVID-19) pandemic. *Ann Intern Med* 2020;173:304–305.
- Jain S, Self WH, Wunderink RG, *et al*. Community-acquired pneumonia requiring hospitalization among US adults. *N Engl J Med* 2015;373:415–427.
- Metlay JP, Waterer GW, Long AC, *et al*. Diagnosis and treatment of adults with community-acquired pneumonia: an official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. *Am J Respir Crit Care Med* 2019;200:e45–e67.
- Rowe HM, Meliopoulos VA, Iverson A, Bomme P, Schultz-Cherry S, Rosch JW. Direct interactions with influenza promote bacterial adherence during respiratory infections. *Nat Microbiol* 2019;4:1328–1336.
- Shah NS, Greenberg JA, McNulty MC, *et al*. Bacterial and viral coinfections complicating severe influenza: incidence and impact among 507 US patients, 2013–2014. *J Clin Virol* 2016;80:12–19.
- Du Y, Tu L, Zhu P, *et al*. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study. *Am J Respir Crit Care Med* 2020;201:1372–1379.
- Cong W, Poudel AN, Alhusein N, Wang H, Yao G, Lambert H. Antimicrobial use in COVID-19 patients in the first phase of the SARS-CoV-2 pandemic: a scoping review. *Antibiotics (Basel)* 2021;10:745.
- Pettit NN, Nguyen CT, Lew AK, *et al*. Reducing the use of empiric antibiotic therapy in COVID-19 on hospital admission. *BMC Infect Dis* 2021;21:516.
- Evans TJ, Davidson HC, Low JM, Basarab M, Arnold A. Antibiotic usage and stewardship in patients with COVID-19: too much antibiotic in uncharted waters? *J Infect Prev* 2021;22:119–125.
- Lucien MAB, Canarie MF, Kilgore PE, *et al*. Antibiotics and antimicrobial resistance in the COVID-19 era: perspective from resource-limited settings. *Int J Infect Dis* 2021;104:250–254.
- Martin AJ, Shulder S, Dobrzynski D, Quartuccio K, Pillinger KE. Antibiotic use and associated risk factors for antibiotic prescribing in COVID-19 hospitalized patients. *J Pharm Pract* 2021. doi: 10.1177/08971900211030248.

37. Andrews A, Budd EL, Hendrick A, *et al.* Surveillance of antibacterial usage during the COVID-19 pandemic in England, 2020. *Antibiotics (Basel)* 2021;10:841.
38. Bork JT, Leekha S, Claeys K, *et al.* Change in hospital antibiotic use and acquisition of multidrug-resistant gram-negative organisms after the onset of coronavirus disease 2019. *Infect Control Hosp Epidemiol* 2021;42:1115–1117.
39. Dieringer TD, Furukawa D, Graber CJ, *et al.* Inpatient antibiotic utilization in the Veterans' Health Administration during the coronavirus disease 2019 (COVID-19) pandemic. *Infect Control Hosp Epidemiol* 2021;42:751–753.